Here are three things to know.
1. The decision slashes 15 percent of the company’s workforce in West Virginia. About 3,000 people will remain employed.
2. A majority of the affected employees work in jobs related to operations.
3. Mylan said the layoffs were because the plant “needed to be rightsized and less complex,” after having a discussion with the FDA. Mylan did not specify the details on the discussion with the federal agency.
More articles on supply chain:
Amazon drops plan to become a major pharmaceutical distributor: 7 things to know
GSK divests line of rare disease drugs
FDA OKs 1st AI medical device that screens patients without physician interpretation
